The microbiology testing market was valued at USD 7.95 billion in 2025 and is expected to reach USD 8.21 billion in 2026 and USD 10.81 billion by 2034, expanding at a CAGR of 5.5% over the forecast period 2026–2034. North America was the largest regional market in 2025. Major companies include Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Beckman Coulter, Bio-Rad Laboratories, bioMérieux SA, Bruker Corporation, Charles River Laboratories International, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Hologic, Merck KGaA, Neogen Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.

Reagents and Consumables Anchor Product Revenue

Reagents and consumables accounted for approximately 42% of the market in 2025, owing to their constant and recurring use in microbiological testing. The category includes culture media, stains, and reagents used in routine testing. Testing kits are projected to grow at a rapid pace, fueled by demand for quick and point-of-care diagnostic tests, as pre-configured kits enable faster processing and improved workflows in hospital and food testing laboratories. Instruments such as incubators and PCR systems complete the product scope.

Rapid Microbiology Testing and AI-Enabled Automation

Rapid microbiology testing is an emerging segment, offering faster detection than traditional methods, with moderate sensitivity in some cases and primary use in industrial quality control and real-time contamination monitoring. In January 2025, Rapid Infection Diagnostics introduced its BSIDx one-button system, which detects microorganisms and antibiotic resistance directly from positive blood cultures in fewer than five hours. In March 2026, LabVantage Solutions developed CORTEX, which combines AI with a LIMS solution to achieve predictive quality control, helping reduce manual intervention and turnaround time. By comparison, culture-based methods dominate the technology landscape, while molecular diagnostics is the fastest-growing segment.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/microbiology-testing-market

Pharmaceutical Microbiology Testing and Regulated Demand

Pharmaceutical microbiology testing supports drug development, quality, and sterility, and pharma and biotech companies are the fastest-growing end-user segment. In December 2025, India announced a USD 7 billion API development program to improve domestic pharmaceutical manufacturing and minimize imports, which has accelerated the market in India, particularly in quality control and contamination testing. Growth in pharmaceutical manufacturing and healthcare spending has also strengthened the market in China. Hospitals and diagnostic laboratories nonetheless led end-use with about 44% share in 2025.

Food Microbiology Testing and Safety Compliance

Food microbiology testing is expected to grow rapidly due to the stringent regulatory environment in the food industry and growth in global trade. The tests are used to identify contaminants in food processing to ensure product quality. Europe, the second-largest market, performs high volumes of testing because of strict compliance needs in pharmaceutical testing, food processing, and water quality.

Digital Laboratories and Antimicrobial Resistance

The report notes that the future of the market is influenced by increasing infections, antimicrobial resistance, and a significant move toward rapid and precise testing in clinical laboratories. Global surveillance programs are also boosting growth. The transition toward digital microbiology laboratories is transforming operations, as automation, image analysis software, and data systems improve the efficiency of culture analysis and result interpretation.

Microbiome Research and Personalized Medicine

New applications are opening growth prospects, including microbiome research that extends testing beyond traditional infectious disease into gut health, metabolic disorders, and immune system disorders. Personalized medicine is creating demand for advanced microbial profiling to guide treatment strategies based on individual microbiota and infection patterns. Decentralized testing and point-of-care solutions are becoming increasingly popular, particularly in resource-limited and outpatient settings.

Cost Considerations

Advanced testing devices and automation solutions require substantial capital, which hinders smaller laboratories. Equipment costs, maintenance, and skilled workforce requirements add complexity, and these barriers affect adoption rates, particularly in resource-limited settings. Integration of AI with Microbiology Testing is seen as creating opportunities for quicker and more accurate testing.

Antimicrobial Susceptibility Testing and Future Outlook

Hospitals, clinical laboratories, and pharmaceutical industries in North America increasingly adopted automated systems to reduce detection time for microbes and antimicrobial susceptibility testing. In March 2026, NVIDIA announced the expansion of its Nemotron and healthcare AI frameworks to support autonomous systems in clinical workflows and drug discovery.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market